Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143246 · ClinicalTrials.gov registry record · Phase 3
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
A Phase 3 study, sponsored by Mallinckrodt.
- Completed
- Registry status
- Phase 3
- Development phase
- 196
- Enrollment target
NCT01143246 is a Phase 3 study that has completed, run by Mallinckrodt. The registered enrollment target is 196 participants.
The verdict
NCT01143246, a Phase 3 study, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 196 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.
Interventions
- DRUG Placebo
- DRUG Terlipressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2010-10-11 |
| Est. Completion | 2013-05-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01143246
The ClinicalTrials.gov registry entry for NCT01143246 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01143246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01143246 about?
NCT01143246 is a clinical study titled "A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin". This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.
What is the current status of trial NCT01143246?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2010-10-11. Estimated completion is 2013-05-10.
What interventions are being tested in trial NCT01143246?
The interventions under investigation include: Placebo (DRUG), Terlipressin (DRUG).
Who is sponsoring clinical trial NCT01143246?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.